SummaryPrimary liposarcoma of the liver is extremely rare. Because of its rarity, the knowledge of the clinical course, management and prognosis of it are limited. Here we report a case of primary myxoid liposarcoma of the liver in an 83-year-old Iranian woman.
BACKGROUND
Basidiobolomycosis is a rare fungal infection caused byBasidiobolus ranaruma worldwide environmental saprophyte fungus that is potentially a pathogen.B ranarummainly affects the subcutaneous tissues but gastrointestinal and disseminated infections rarely have been reported previously. We report a case ofB ranaruminfection in a 12-year-old immunocompetent boy presented with abdominal pain from 2 months earlier before admission in the hospital. Abdominal CT scan revealed a lobulated mass-like lesion in the vicinity of right lower quadrant enveloping ascending colon and terminal ileum with involvement of mesentery. Histopathological examination showed severe full-thickness infiltration of inflammatory cells mainly eosinophils admixed with multinucleated giant cells and large areas of necrosis with granulomatous feature. Periodic acid Schiff staining demonstrated thin-walled septate fungal hyphae's surrounded by eosinophilic material (Splendore-Hoppeli phenomenon) identified as a basidiobolomycosis.
The obliteration of the arterial vascular system of toes is considered as a potentially catastrophic event in clinical practices. In most instances, the cessation of arterial blood flow heralds a serious underlying pathology. A definite classification of some cases is somehow difficult and subject to diagnostic challenges. The aim of the present case study is to share and discuss potentially complex and multifactorial mechanisms of some acute vascular events. In this report, we deal with a 46-year-old man with a rather gradual-onset ischemia of his toe who responded favorably to a combination of pulsed glucocorticoid and anticoagulation within a week.
Introduction: Laparoscopic cholecystectomy is the standard treatment of cholecystitis. In comparison to open surgery, it has advantages such as a shorter recovery period and a shorter hospital stay. One of the side effects of this treatment is abdominal and shoulder pain after surgery. The purpose of this study was to see how intraperitoneal dexamethasone affects abdominal and shoulder pain following laparoscopic cholecystectomy. Methods and materials: This study included 70 patients aged 18-70 years who were candidate for laparoscopic elective cholecystectomy. Using a random number table, patients were separated into two equal groups. In the first group, after laparoscopy and before trocar removal, 20 cc of ringer serum containing 8 mg dexamethasone was sprayed in the diaphragm and peritoneal cavity, and in the second group, 20 cc ringer was sprayed. Visual analog scale (VAS) pain score was used to assess post operation pain. Results: From 6 o'clock on, there was a substantial difference in abdominal pain between the two groups, with the control group experiencing higher pain. From 12 o'clock onwards, there was a strong association between shoulder discomfort in the two groups, and patients in the control group experienced more pain. Furthermore, the control group received more opioids. Patients in the control group experienced higher nausea and vomiting starting 12 hours after surgery. Conclusion: After laparoscopic surgery, dexamethasone can relieve abdominal and shoulder discomfort, as well as nausea and vomiting, and it can also reduce the need for opioids. Dexamethasone appears to be effective in minimizing postoperative complications. Keywords: Postoperative Pain, Intraperitoneal, Dexamethasone, Laparoscopy
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.